Aura Biosciences (NASDAQ:AURA - Get Free Report)'s stock had its "buy" rating reiterated by investment analysts at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports. They presently have a $22.00 price objective on the stock. HC Wainwright's target price points to a potential upside of 228.85% from the stock's current price. HC Wainwright also issued estimates for Aura Biosciences' Q3 2025 earnings at ($0.47) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($1.99) EPS, FY2026 earnings at ($2.15) EPS, FY2027 earnings at ($1.97) EPS, FY2028 earnings at ($1.70) EPS and FY2029 earnings at ($1.32) EPS.
Separately, JMP Securities reissued a "market outperform" rating and issued a $19.00 price target on shares of Aura Biosciences in a research report on Friday, May 23rd. Six investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, Aura Biosciences has an average rating of "Buy" and a consensus target price of $22.00.
Check Out Our Latest Analysis on Aura Biosciences
Aura Biosciences Trading Down 0.4%
Shares of AURA traded down $0.03 during midday trading on Wednesday, hitting $6.69. The stock had a trading volume of 154,768 shares, compared to its average volume of 219,353. The firm has a market cap of $415.58 million, a P/E ratio of -3.41 and a beta of 0.46. The business has a 50-day simple moving average of $6.62 and a two-hundred day simple moving average of $6.51. Aura Biosciences has a fifty-two week low of $4.34 and a fifty-two week high of $12.38.
Aura Biosciences (NASDAQ:AURA - Get Free Report) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.02. On average, analysts expect that Aura Biosciences will post -1.66 earnings per share for the current fiscal year.
Insider Buying and Selling
In other Aura Biosciences news, SVP Amy Elazzouzi sold 7,722 shares of the business's stock in a transaction on Monday, August 18th. The shares were sold at an average price of $6.70, for a total value of $51,737.40. Following the sale, the senior vice president owned 86,558 shares of the company's stock, valued at $579,938.60. The trade was a 8.19% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 6.30% of the stock is currently owned by company insiders.
Institutional Trading of Aura Biosciences
Several institutional investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC increased its holdings in shares of Aura Biosciences by 49.3% during the second quarter. Tower Research Capital LLC TRC now owns 6,372 shares of the company's stock worth $40,000 after buying an additional 2,104 shares in the last quarter. BNP Paribas Financial Markets acquired a new position in Aura Biosciences during the 4th quarter worth about $50,000. GAMMA Investing LLC lifted its position in Aura Biosciences by 5,766.9% during the 1st quarter. GAMMA Investing LLC now owns 9,739 shares of the company's stock valued at $57,000 after purchasing an additional 9,573 shares during the period. Invesco Ltd. acquired a new stake in Aura Biosciences during the 2nd quarter worth $76,000. Finally, Bridgeway Capital Management LLC bought a new stake in Aura Biosciences in the second quarter valued at about $102,000. Institutional investors and hedge funds own 96.75% of the company's stock.
About Aura Biosciences
(
Get Free Report)
Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
See Also
Before you consider Aura Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aura Biosciences wasn't on the list.
While Aura Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access